[The guidelines for diagnosis and treatment of myeloma bone disease in China (2022)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):979-985. doi: 10.3760/cma.j.issn.0253-2727.2022.12.002.
Abstract
摘要
相似文献
1
[The guidelines for diagnosis and treatment of myeloma bone disease in China (2022)].《中国骨髓瘤骨病诊断与治疗指南（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):979-985. doi: 10.3760/cma.j.issn.0253-2727.2022.12.002.
2
[Guidelines for treatment of myeloma bone disease].[骨髓瘤骨病治疗指南]
Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):721-3.
3
Myeloma bone disease.骨髓瘤骨病
J Bone Miner Res. 2009 Nov;24(11):1783-8. doi: 10.1359/jbmr.090901.
4
Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.模仿骨髓瘤骨病的溶骨性Richter综合征慢性淋巴细胞白血病未显示DKK1过表达。
Leuk Lymphoma. 2006 Sep;47(9):1987-8. doi: 10.1080/10428190600687539.
5
Current Controversies in the Management of Myeloma Bone Disease.骨髓瘤骨病管理中的当前争议
J Cell Physiol. 2016 Nov;231(11):2374-9. doi: 10.1002/jcp.25351. Epub 2016 Mar 10.
6
Guidelines for the diagnosis and management of multiple myeloma 2011.2011年多发性骨髓瘤诊断与管理指南
Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14.
7
Pathophysiology and management of bone disease in multiple myeloma.多发性骨髓瘤骨病的病理生理学与管理
Cancer Invest. 1997;15(1):85-90. doi: 10.3109/07357909709018921.
8
Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma.多发性骨髓瘤嵌合抗原受体 T 细胞治疗相关的骨骼疾病的管理。
Crit Rev Oncol Hematol. 2024 Sep;201:104429. doi: 10.1016/j.critrevonc.2024.104429. Epub 2024 Jun 26.
9
[Prevention and treatment of multiple myeloma bone disease].[多发性骨髓瘤骨病的防治]
Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):292-4. doi: 10.3760/cma.j.issn.0253-2727.2013.04.007.
10
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].中国多发性骨髓瘤诊断与治疗指南（2015年修订版）：复发/难治性多发性骨髓瘤治疗解读
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):93-4. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004.
本文引用的文献
1
UK clinical guideline for the prevention and treatment of osteoporosis.英国临床骨质疏松症预防和治疗指南。
Arch Osteoporos. 2022 Apr 5;17(1):58. doi: 10.1007/s11657-022-01061-5.
2
The role of bone-modifying agents in myeloma bone disease.骨修饰剂在骨髓瘤骨病中的作用。
JBMR Plus. 2021 Jun 15;5(8):e10518. doi: 10.1002/jbm4.10518. eCollection 2021 Aug.
3
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.基于 MY-RADS 标准的扩散加权全身 MRI（DW-MRI）成像反应对自体干细胞移植后多发性骨髓瘤患者的预测作用，并与流式细胞术 MRD 评估相结合的评估。
Cancer Med. 2021 Sep;10(17):5859-5865. doi: 10.1002/cam4.4136. Epub 2021 Jul 15.
4
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.多发性骨髓瘤相关骨病的治疗：国际骨髓瘤工作组骨工作组的建议。
Lancet Oncol. 2021 Mar;22(3):e119-e130. doi: 10.1016/S1470-2045(20)30559-3. Epub 2021 Feb 2.
5
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.靶向间充质基质细胞中的异常 DNA 甲基化作为骨髓瘤骨病的治疗方法。
Nat Commun. 2021 Jan 18;12(1):421. doi: 10.1038/s41467-020-20715-x.
6
Is whole body low dose CT still necessary in the era of F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?在 F-FDG PET/CT 评估多发性骨髓瘤患者骨骼疾病的时代，全身低剂量 CT 还有必要吗？
Hell J Nucl Med. 2020 Sep-Dec;23(3):264-271. doi: 10.1967/s002449912206. Epub 2020 Dec 14.
7
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients.成像在多发性骨髓瘤患者微小残留病评估中的作用
J Clin Med. 2020 Oct 31;9(11):3519. doi: 10.3390/jcm9113519.
8
Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma.弥散加权磁共振成像的基线骨髓表观扩散系数值：新诊断多发性骨髓瘤患者疾病进展和死亡的潜在独立预测指标
Eur Radiol. 2021 Apr;31(4):1843-1852. doi: 10.1007/s00330-020-07295-6. Epub 2020 Sep 23.
9
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.骨髓瘤骨病的发病机制及 NRF2 的可能作用
Int J Mol Sci. 2020 Sep 14;21(18):6723. doi: 10.3390/ijms21186723.
10
Quantitative bone marrow magnetic resonance imaging through apparent diffusion coefficient and fat fraction in multiple myeloma patients.多发性骨髓瘤患者骨髓磁共振弥散加权成像表观扩散系数和脂肪分数定量分析
Radiol Med. 2021 Mar;126(3):445-452. doi: 10.1007/s11547-020-01258-z. Epub 2020 Aug 18.
Zotero 插件